代谢综合征并不增加下尿路症状和良性前列腺增大患者的射精功能障碍风险:一项意大利单中心队列研究
该研究纳入2012至2016年在本院前列腺门诊就诊的220例下尿路症状伴良性前列腺增大男性,前瞻性数据库中用IPSS、IIEF-SF和MSHQ-EjD-SF评估,代谢综合征按ATP III标准定义。48/220例(22%)有代谢综合征,109/220例(50%)存在中度或重度射精功能障碍;多因素分析中代谢综合征并非射精功能障碍的预测因素,年龄、IIEF评分和IPSS是预测因素。
要点
- 220例中48例(22%)合并代谢综合征,109例(50%)存在中度或重度射精功能障碍。
- 多因素分析示年龄(OR 1.058)、IIEF评分(OR 0.899)和IPSS(OR 1.065)为射精功能障碍的预测因素。
- 在本系列中代谢综合征未显示为射精功能障碍的预测因素,对MSHQ-EjD-SF评估的射精功能障碍无影响。
核心结论
- 在本单中心研究中,代谢综合征对以MSHQ-EjD-SF评估的射精功能障碍无影响。
研究设计与样本
- 2012至2016年,连续纳入本院前列腺门诊就诊的下尿路症状伴良性前列腺增大男性,纳入前瞻性数据库。
- 共220例患者入组,48/220例(22%)存在代谢综合征;代谢综合征按成人治疗组III(ATP III)标准定义。
- 所有患者均以国际前列腺症状评分(IPSS)、国际勃起功能指数简表(IIEF-SF)和男性性健康问卷射精功能障碍简表(MSHQ-EjD-SF)评估,后者评估射精能力、射精力量、射精量和与射精功能障碍相关的主观困扰。
主要发现
- 平均年龄70±8岁,平均IPSS为8.3±6.2,平均IIEF评分为17.3±7.9,平均MSHQ-EjD-SF为9.9±4.7。
- 总体109/220例(50%)存在中度或重度射精功能障碍。
- 多因素分析中,年龄(OR 1.058,95%CI 1.016-1.123;P=.007)、IIEF评分(OR 0.899,95%CI 0.856-0.943;P=.000)和IPSS(OR 1.065,95%CI 1.011-1.123;P=.018)为射精功能障碍的预测因素。
- 在本系列中代谢综合征未显示为射精功能障碍的预测因素。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the relationship between metabolic syndrome (MetS) and ejaculatory dysfunction (EjD) in patients with lower urinary tract symptoms and benign prostatic enlargement. MATERIALS AND METHODS: From 2012 to 2016, a consecutive series of men with lower urinary tract symptoms and benign prostatic enlargement who were attending our prostate clinic were evaluated using the International Prostate Symptom Score (IPSS) and were subsequently enrolled into a prospective database. All patients were assessed using the short form of the International Index of Erectile Function (IIEF-SF) and the Male Sexual Health Questionnaire ejaculatory dysfunction short form (MSHQ-EjD-SF) that evaluates the ability to ejaculate, the ejaculation force, the ejaculation volume, and subjective bother associated with EjD. MetS was defined according to the Adult Treatment Panel III criteria. RESULTS: A total of 220 patients were enrolled; 48 of 220 patients (22%) presented a MetS. Mean age was 70 ± 8 years, mean IPSS was 8.3 ± 6.2, mean IIEF score was 17.3 ± 7.9, and mean MSHQ-EjD-SF was 9.9 ± 4.7. Overall, 109 of 220 patients (50%) were affected by a moderate or severe EjD. On multivariate analysis, age (odds ratio [OR]: 1.058, 95% confidence interval [CI]: 1.016-1.123; P = .007), IIEF score (OR: 0.899, 95% CI: 0.856-0.943; P = .000), and IPSS (OR: 1.065, 95% CI: 1.011-1.123; P = .018) were found to be predictors of EjD. In our series MetS was not found to be predictive of EjD. CONCLUSION: In our single-center study, MetS has no influence on the EjD evaluated with the MSHQ-EjD-SF.
引用
- De Nunzio C, Lombardo R, Gacci M, et al. Metabolic Syndrome Does Not Increase the Risk of Ejaculatory Dysfunction in Patients With Lower Urinary Tract Symptoms and Benign Prostatic Enlargement: An Italian Single-center Cohort Study. Urology. 2017. PMID: 28412335. doi:10.1016/j.urology.2017.04.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。